Q BIOMED PARTNER MANNIN RESEARCH EXECUTIVES ATTENDING OIS@AAO 2016 & AAO

Ophthalmology Summits Attract Broad Range of Industry Professionals

NEW YORK, October 13, 2016 — Q BioMed Inc. (OTCQB: QBIO), technology partner Mannin Research Inc will participate at the the Ophthalmology Innovation Summit  and the American Academy of Ophthalmology Annual Meeting in Chicago IL.

Mannin Research Inc. will be attending the Ophthalmology Innovation Summit (OIS@AAO 2016), which takes place on October 13th 2016 in Chicago, Illinois. The OIS facilitates meaningful interactions and business partnerships between physicians, entrepreneurs, investors, and industry executives who are driving ophthalmic innovation.

The Ophthalmology Innovation Summit is held in conjunction with the American Academy of Ophthalmology Annual Meeting (AAO 2016). The American Academy of Ophthalmology is the world’s largest association of eye physicians and surgeons. The AAO Annual Meeting runs from October 14-18. Mannin Research executives will be attending both OIS and AAO this year to meet with academics and industry professionals.

The meeting provides Mannin executives the opportunity to further explore business development goals and other collaborative opportunities for the MAN-01 program for treatment of glaucoma.

Q BioMed Inc. CEO, Denis Corin said, “Given the recent uptick in M&A and significant interest in high value ophthalmology assets we expect this to be a very productive conference. “

Please visit our website www.qbiomed.com to sign up for regular updates and stay up-to-date with our progress.

 About Q BioMed Inc.

Q BioMed Inc.”Q“ is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital the need to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Denis Corin

CEO

Q BioMed Inc.

1 888 357 2435
Source: Q BioMed Inc.

Share

Q BIOMED DRUG DEVELOPMENT PARTNER TO ATTEND EANM 2016 in BARCELONA, SPAIN October 15-19 2016

Annual European Association Nuclear Medicine Congress Most Valuable Meeting World Wide

NEW YORK, October 18, 2016 — Q BioMed Inc. (OTCQB: QBIO), drug development partner will attend the European Association of Nuclear Medicine (EANM) meeting in Barcelona, Spain.

With more than 130 Sessions, the EANM Annual Congress is the most valuable Nuclear Medicine Meeting worldwide. Each year, more than 5,500 participants have the possibility to network, socialise and discuss the newest trends and findings in the field of Nuclear Medicine. The EANM has approximately 2,100 abstracts annually from all over Europe and overseas. 130 exhibiting companies, covering an area of 3,000 sqm present their newest technologies.  

Members of the Q BioMed advisory group and technology partners will be meeting with industry colleagues and collaborators s of materials required for the scale up and production of Q BioMeds recently licenced, FDA approved, SR89 drug. This licensed radiopharmaceutical agent is indicated for the treatment of pain associated with metastatic bone cancer. SR89  provides long lasting relief for patients suffering from bone pain due to metastatic cancer, typically caused by advanced-stage breast, prostate or lung cancer. The drug is preferentially absorbed in bone metastases, it has been proven to provide a long-term effect resulting in non-­narcotic cancer pain relief and enhanced quality of life.  

There are approximately 300,000 new cases of bone metastases in patients with breast and lung cancer per year in the U.S. alone.  Approximately 80% of patients using SR89 have reported experiencing a substantial decrease in pain, an increase in physical activity and a reduction in the need for opiate analgesics, such as morphine.

Q BioMed CEO, Denis Corin said, “Key raw materials required for the manufacturing of the drug are sourced from Europe and this meeting provides an ideal opportunity to meet with all the relevant suppliers and stakeholders. These relationships and the agreements that result from these meetings are an important milestone as we begin roll out of the manufacturing process.”

We expect to update the market with details surrounding the strategic milestones related to the production and delivery of this drug to market once they are finalized.

Please visit our website www.qbiomed.com to sign up for regular updates and stay up-to-date with our progress.

About Q BioMed Inc.

Q BioMed Inc.”Q“ is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital the need to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Denis Corin

CEO

Q BioMed Inc.

1 888 357 2435
Source: Q BioMed Inc.

Share

Q BIOMED INC. Technology Partner Mannin Research Inc. to participate in a webcast on innovating for ophthalmic diseases

Webcast, part of the Nature.Com BioPharma Dealmakers series, is scheduled for 10:00 am ET on October 20th.

NEW YORK, October 19, 2016 — Q BioMed Inc. (OTCQB: QBIO), technology partner Mannin Research Inc. will present in a webcast on Innovating for Ophthalmic Diseases on October 20th at 10AM ET.

Dr. George Nikopoulos, CEO and President of Mannin Research Inc. will participate in a BioPharma Dealmakers webcast, sponsored in part by Mannin Research Inc., featuring three companies innovating in therapies for eye disorders.

Please register here to participate > Webcast registration link

This webcast will explore some of the latest advances in the ophthalmic field through discussion with representatives from companies developing a range of innovative therapies for eye disorders, including the use of iPS cells, eye drops to deliver small-molecule drugs and complement inhibition.

The webcast will conclude with a live roundtable discussion and a Q&A section to allow you to participate and put your own questions to the speakers.

Dr. Nikopoulos has worked with and advised a number of biotechnology, pharmaceutical and med-tech companies. Dr. Nikopoulos’ expertise includes translating complex technologies and innovations into strategies for commercialization, market research, and business development as well as pre-clinical toxicology study design.

Other webcast participants include:

• Hardy TS Kagimoto, MD, President, Representative Director and CEO of HEALIOS K.K.
• Dr. George Nikopoulos, CEO & President of Mannin Research Inc.

• Moderator: Raveena Bhambra, Editor of BioPharma Dealmakers. Raveena has worked in the biopharma industry for over 10 years specifically in the areas of dealmaking, partnering and licensing.

More information can be found on the following social media links

https://www.linkedin.com/company/nature-publishing-group

https://www.linkedin.com/pulse/next-webcast-innovating-ophthalmic-diseases-expert-share-burridge?trk=prof-post

https://biopharmadealmakers.nature.com/users/5061-samia-burridge/posts/11429-next-webcast-innovating-for-ophthalmic-diseases

https://twitter.com/bpdealmakers/status/775681066401234944

https://twitter.com/Samia_Burridge/status/781490796801425408

https://www.facebook.com/NatureReviews/

About the Webcast

BioPharma Dealmakers webcasts are dedicated to small and large companies looking for commercial partnerships.  Read the quarterly BioPharma Dealmakers supplement in Nature Biotechnology and Nature Reviews Drug Discovery.

About Mannin Research Inc.

Mannin Research Inc. (Mannin), is a privately held, research stage biotechnology company, founded in July, 2012. Mannin is focused on the discovery, development, and commercialization of first-in-class therapeutics for vascular diseases using the Tie2 mechanism of action. Mannin’s research is led by Chief Scientific Officer, Dr. Susan Quaggin, Chief of Nephrology and Director of the Feinberg Institute at Northwestern University.

With a formal research partnership with Northwestern University, revenue generating research and development and licensing agreement with QBioMed (OTCQB: QBIO), Mannin is leading the development of a new class of compounds for a range of vascular diseases. Our primary program, MAN-01, is for treatment of Primary Open-Angle Glaucoma.

More information is available at http://mannin.ca/.

Contact:

info@mannin.ca

416 775 9767

About Q BioMed Inc.

Q BioMed Inc.”Q“ is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital the need to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. Further, in the event that the company with which we have recently signed a license/acquisition agreement subject to conditions fails to satisfy such conditions by closing, we will not proceed with the transaction. Other than update the status of the the aforementioned license/acquisition, we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Denis Corin

CEO

Q BioMed Inc.

www.QbBioMed.com

1 888 357 2435

Share

Q BIOMED INC. ANNOUNCES ENTRY INTO DEFINITIVE FUNDING AGREEMENT FOR UP TO $4,000,000

Capital injection provides runway to bring FDA approved cancer palliation drug to market in early 2017 and continue advancing our glaucoma drug.

NEW YORK, November 30, 2016 — Q BioMed Inc. (OTCQB: QBIO), is pleased to announce that it has entered into a definitive agreement with Yorkville Advisors Global (“Yorkville”) for up to $4,000,000 of convertible debentures. We have closed on the initial tranche of $1,500,000 and expect to close on the balance pending the effective registration of the underlying shares.

The conversion of the Yorkville debentures shall be at the lower of $4.00 or a 7% discount to market, with a floor price of $2.00. Please see our 8-K filing today for further details.

Q BIoMed Inc. CEO, Denis Corin said, “We are very pleased to partner with Yorkville at this very exciting time in our evolution. Having a revenue ready drug in hand with the capital to execute on the production, manufacturing and roll out of the drug provides a real catalyst for Q BioMed. In addition to the near term revenue, we see significant upside in both the treatment of metastatic bone cancer (palliation) with our Strontium Chloride 89 radiopharmaceutical (“SR89”) as well as the continued development of the Man-01 glaucoma drug.”

SR89 is indicated for the treatment of pain associated with metastatic bone cancer. The generic radiopharmaceutical provides long lasting relief for patients suffering from debilitating bone pain due to metastatic cancer, typically caused by advanced-stage breast, prostate or lung cancer. It has been proven to provide a long-term effect resulting in non-­narcotic cancer pain relief and enhanced quality of life.

There are approximately 350,000 cases of patients living with bone metastases in the US alone. An additional 380,000 new diagnoses of patients with breast and lung cancer per year and approximately 1 in 3 of those will develop bone metastases.  Approximately 80% of patients using SR89 have reported experiencing a substantial decrease in pain, an increase in physical activity and a reduction in the need for opiate analgesics, such as morphine. This represents a very significant market and an opportunity to bring an effective and much needed product to many patients in need.

Please visit our website www.qbiomed.com to sign up for regular updates and stay up-to-date with our progress.

About Q BioMed Inc.

Q BioMed Inc.”Q“ is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital the need to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Denis Corin

CEO

Q BioMed Inc.

1 888 357 2435

Source: Q BioMed Inc.

Share

Q BIOMED INC. TO PRESENT AT BIOTECH SHOWCASE 2017 IN SAN FRANCISCO JAN 9 – 11th

Management reviews 2016 and looks ahead to 2017

NEW YORK, 5 January, 2017 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration and development company will present at the  9th Annual Biotech Showcase™ 2017 being held January 9-11, 2017 at the Hilton San Francisco Union Square, California. Taking place during one of the industry’s largest annual healthcare investor conferences, this investor and partnering conference attracts pharmaceutical executives from around the world focused on investment and business development opportunities in the life sciences industry.

Conference Presentation Details:

Presenter: Denis Corin – CEO

Where:  Hilton San Francisco Union Square, 333 O’Farrell Street, San Francisco, CA 94102  

When:  Tuesday, January 10, 2017

Time: 8:00 AM

Room:   Room 3 – Ballroom Level  

Webcast: https://event.webcasts.com/viewer/event.jsp?ei=1130761 live and replay 2hr after the event.

Conference Website:  Biotech Showcase 2017

Q BioMed management will host one-on-one meetings with investors at the conference between January 9-11, 2017. To meet with us, please submit a meeting request via the PartneringOne scheduling system.

In addition we provide this update to those unable to attend.

2016 was essentially our inaugural year, being our first full calendar year pursuing innovative opportunities in the biotechnology space. It was a very busy year as the Company established itself in the space and commenced its effort to find innovative technologies and management teams with inherent, yet unrealized, value. By adding strategic resources to accelerate the development of those technologies, we hope to realize that value.

We closed 2016 with two pipeline technologies under the ‘Q’ umbrella; essentially bookends of the multi-asset business model we are building. One early stage, opportunity in the highly sought after glaucoma space and one FDA approved, drug for bone cancer palliation. In addition, we recently secured the funding to allow us to execute on the near term milestones to advance our business.

Over the course of the next several months we will continue performing due diligence on additional attractive assets with the goal of adding one or more to our pipeline in calendar 2017.

Review of Strontium Chloride 89 Injection (SR89):

In September 2016 we licensed an FDA approved drug that provides relief for patients suffering from debilitating bone pain due to metastatic cancer, typically caused by advanced-stage breast, prostate or lung cancer. It has been proven to provide a long-term effect resulting in cancer pain relief and enhanced quality of life.

Revenue from sales of our non-narcotic pain palliative drug will be a major catalyst for Q BioMed and we look forward to providing additional guidance on the timing of this in the near future.

Review of Man-01 our glaucoma asset licensed from Mannin Research Inc:

The MAN-01 asset for treatment of Primary Open Angle Glaucoma (POAG), is continuing to progress in its pre-clinical lead candidate optimization of a small molecule for a topical application.

Mannin will continue with preclinical research and development activities for 2017 before progressing into IND enabling studies, expected in 2018 to be followed by first in human proof-of-concept clinical trials.

Our efforts in establishing research and development partnerships with commercial partners, as well as government organizations to provide technical and financial support for the development of MAN-01 for POAG is ongoing. To this end, Mannin is continuing strategic partnership discussions with companies and technologies that will strengthen its intellectual property portfolio in the Tie2/TEK mechanism of action market.

Thank you for your interest in Q BioMed and we hope you continue following our progress.

Happy New Year and may it bring you good health, happiness and prosperity!

Please visit our website www.qbiomed.com to sign up for regular updates and stay up-to-date with our progress. www.qbiomed.com

About Q BioMed Inc.

Q BioMed Inc.”Q“ is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital the need to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy, revenue generation and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Denis Corin

CEO

Q BioMed Inc.

1 888 357 2435

Source: Q BioMed Inc.

Copyright © 2017 PR Newswire. All Rights Reserved

http://qbiomed.com/wp-content/uploads/2017/02/QBIO-Profile-FEB-2017.pdf

NEW YORK, February 7, 2017 – Q BioMed, Inc. (OTCQB: QBIO) has entered into an agreement with the Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB) to develop a chemotherapeutic technology to treat liver cancer.

The technology will utilize “uttroside B” and the compound’s derivatives as a chemotherapeutic agent against hepatocellular carcinoma. The preclinical efficacy of uttroside B, a potent saponin, against liver cancer was recently demonstrated in a November 3, 2016 study published in Scientific Reports, a Nature journal.

The compound has been isolated and characterized from the leaves of Solanum nigrum Linn, a plant widely used in traditional medicine. In the Scientific Reports study, researchers showed that in animal models, uttroside B was ten times more cytotoxic to the HepG2 liver cancer cell line than the only drug currently approved by the Food and Drug Administration for liver cancer.

Uttroside B drastically shrunk tumors in mice bearing human liver cancer xenografts. In addition, in pre-clinical experiments uttroside B induced cytotoxicity in all liver cancer cell lines, irrespective of their hepatitis B virus status, while being non-toxic to normal immortalized hepatocytes.

Chemotherapeutic options for liver cancer are limited, and the prognosis of patients remains challenging. According to the Centers for Disease Control and Prevention, it is the second most common cause of cancer deaths worldwide, claiming approximately 750,000 lives each year. In the US, the American Cancer Society estimates that 39,000 people will be diagnosed with primary liver cancer in 2017 and that 27,000 will die from the disease this year.

The currently available drug has been shown to increase survival by only a short period of time. That drug also been reported to carry a variety of serious side effects, including increased blood pressure, bleeding problems, decreased blood flow to the heart and heart attacks.

In the Scientific Reports study, uttroside B was shown to be several times more potent than the currently available drug and did not cause noticeable side effects in vitro or in vivo.

“We are encouraged by the preclinical results we observed in this data and look forward to working with our collaborators at OMRF and RGCB to carry out further pre-clinical and clinical evaluation of uttroside B,” Q BioMed Inc. CEO Denis Corin said. “Our ultimate goal is to use it as an effective chemotherapeutic against liver cancer, which currently has very few therapeutic options.”

The uttroside B technology is covered by a provisional patent application. To see the full Scientific Reports study, go to: http://www.nature.com/articles/srep36318

Please visit www.qbiomed.com to stay up to date and follow our progress.

About Q BioMed Inc.

Q BioMed Inc. (Q) is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital the need to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

About OMRF

OMRF (omrf.org) is an independent, nonprofit biomedical research institute dedicated to understanding and developing more effective treatments for human diseases. Its scientists focus on such critical research areas as cancer, diseases of aging, lupus and cardiovascular disease.

About RGCB

RGCB is an autonomous national institution fully owned by the Government of India. It does pioneering research in cellular and molecular mechanisms of human animal and plant disease by amalgamating theory, modeling, simulation and experimental science.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact

Denis Corin, CEO

Q BioMed Inc.

1 888 357 2435

Source: Q BioMed Inc.

COMPANY GEARS UP FOR PRODUCTION OF CANCER PAIN PALLIATION DRUG WITH COMMERCIAL LAUNCH EXPECTED IN Q2 2017

NEW YORK, March 22, 2017 — Q BioMed Inc. (OTCQB: QBIO), has closed on its 2nd tranche of the $4,000,000 funding announced on November 30th 2016. The company received $1,000,000 on the 2nd closing bringing the total received to date to $2.5MM. We expect to receive the remaining $1.5MM upon on effectiveness of our recently filed registration statement on Form S-1.

In addition, we are pleased to announce that we have begun process validation for the manufacturing of a non-narcotic analgesic treatment for pain associated with metastatic bone cancer. The drug, generic Strontium Chloride 89 injection, provides long-lasting relief for patients suffering from debilitating bone pain due to metastatic cancer, typically caused by advanced-stage breast, prostate or lung cancer. It has been proven to provide a long-term effect, resulting in cancer pain relief and enhanced quality of life.

There are approximately 350,000 cases of patients living with bone metastases in the U.S. alone. In addition, 380,000 new diagnoses of patients with breast, prostate and lung cancer occur every year and approximately 1 in 3 of those will develop bone metastases.

The delivery of an affordable, non-narcotic pain therapy is a much needed and underutilized option for this patient population and coincides well with the recently passed 21st Century Cures Act combating opiate overuse and abuse. The Act, provides $1 billion in funding over the next two years for opioid addiction prevention and treatment programs to develop, promote and use non-narcotic alternative therapies.

The commercialization of the drug allows us to deliver an effective and much needed alternative to hundreds of thousands of suffering patients. We are very pleased to offer this U.S. Food and Drug administration approved therapy to patients in the very near term. We are currently negotiating US based contract manufacturing organization (CMO) agreements and expect to have those completed along with the commercial launch in Q2 2017.

Please visit our website www.qbiomed.com to sign up for regular updates and stay up-to-date with our progress.

About Q BioMed Inc.

Q BioMed Inc.”Q“ is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital the need to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Denis Corin

CEO

Q BioMed Inc.

1 888 357 2435

Source: Q BioMed Inc.

Q BIOMED INC. COMPLETES FINAL CLOSING ON $4,000,000 FUNDING

COMPANY USES CAPITAL TO ADVANCE BUSINESS AND EXPAND PIPELINE

NEW YORK, April 10, 2017 — Q BioMed Inc. (OTCQB: QBIO), has closed on its final tranche of the $4,000,000 funding announced on November 30th 2016. The company received $1,500,000 less fees on the final closing bringing the total gross funds received to date to $4MM.

Capital from the transaction will be used to advance our business plan and pipeline as we commercialize our first asset, Strontium Chloride 89 injection (SR89). SR89 is indicated for bone pain palliation, providing long-lasting relief for patients suffering from debilitating bone pain due to metastatic cancer, typically caused by advanced-stage breast, prostate or lung cancer.

Last week Q BioMed management attended the 2017 OMRF BioVenture Forum, an industry event organized and hosted by the Oklahoma Medical Research Foundation (OMRF) where we advanced discussions on the development of a novel liver cancer drug candidate. Approximately, 700,000 people annually throughout the world are diagnosed with liver cancer and approximately 600,000 deaths annually are attributed to liver cancer. Chemotherapeutic options for liver cancer are limited and the prognosis of liver cancer patients remains very poor.

Management met with industry colleagues as well as the Governor of Oklahoma, Mary Fallin, at a reception hosted by the Governor.  We look forward to working with all parties on this important drug, in what is a vibrant biotechnology corridor in Oklahoma City.

Oklahoma Medical Research Foundation (OMRF) BioVenture Forum on Tuesday, April 4, 2017 in Oklahoma City, Okla. (Photo Provided by Oklahoma Medical Research Foundation.)
left to right: William Rosenstadt (QBioMed), Gov. Mary Fallin, Denis Corin (CEO – QBioMed)

The capital also allows us advance discussions with potential additional assets as we continue to develop our drug pipeline.

Please visit our website www.qbiomed.com to sign up for regular updates and stay up-to-date with our progress.

About Q BioMed Inc.

Q BioMed Inc.”Q“ is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital the need to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Denis Corin

CEO

Q BioMed Inc.

1 888 357 2435

Source: Q BioMed Inc.

COMPANY ADDS HIGHLY EXPERIENCED INDUSTRY ADVISORS TO ITS STRATEGIC RESOURCE TEAM

NEW YORK, April 13, 2017 —  Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to announce the appointment of Dr. Amy Ripka and Dr. Rick Panicucci to its board of scientific advisors.

Dr. Amy Ripka is Executive Director of Medicinal Chemistry at WuXi AppTec. She started her career at Bristol Myers Squibb and over 17 years has worked in various capacities in medicinal chemistry with many small companies, including EnVivo (FORUM) Pharmaceuticals as Head of Chemistry, Infinity, Daiamed, HydraBiosciences and FoldRx. Her current responsibilities include strategic planning in medicinal chemistry, early library drug design utilizing multiple in silico methods, hit optimization and overall screening architectures to advance early stage compounds through Phase I-II clinical development.

Dr. Ripka’s therapeutic specialties include Neuroscience, Oncology, Thrombosis and Anti-Infective Disease areas. She has led multiple early stage programs resulting in four clinical candidates, two of which are marketed drugs. Her career has spanned big pharma, biotech and CROs where she has made significant contributions to each of these.

Dr. Ripka, was elected by her peers to Chair the prestigious Medicinal Chemistry Gordon Research Conference and is currently serving a second elected term as the Industrial Councilor for the MEDI Division of the American Chemical Society.

Dr. Ripka, received her Ph.D. in Chemistry from the University of Wisconsin-Madison with a double concentration in organic and medicinal chemistry, and did her post-doctoral studies with Nobel Laureate K. Barry Sharpless from The Scripps Research Institute. Dr. Ripka will advise Mannin’s scientific development and growth.

Dr. Rick Panicucci is the Vice President of Pharmaceutical Development at WuXi AppTec. He is responsible for providing scientific leadership in the areas of Developability, Formulation Development and GMP Manufacturing.

Dr. Panicucci plays an important role in the early stages of drug discovery for various companies. His responsibilities include solid state chemistry and formulation development of all small molecule therapeutics in early development, and developing novel drug delivery technologies for small molecules and large molecules including siRNA.

Prior to WuXi he held the position of Global Head of Chemical and Pharmaceutical Profiling (CPP) at Novartis from 2004 to 2015, where he led the development and implementation of innovative dosage form designs and continuous manufacturing paradigms. He has also held positions as the Director of Formulation Development at Vertex Pharmaceuticals and Senior Scientist at Biogen.

Dr. Panicucci received his Ph.D. in Physical Organic Chemistry at the University of Toronto, and has two post doctoral fellowships at University of California at Santa Barbara and the Ontario Cancer Institute. Dr. Panicucci will advise our technology partner, Mannin Research Inc.’s development both scientifically and commercially.

Both Amy and Rick have been working with Mannin in the development plan for MAN-01, a novel drug candidate for the topical treatment of open-angle glaucoma. George Nikopoulos, CEO of Mannin stated, “We are very pleased to formally welcome Amy and Rick to the team. Amy and Rick bring unparalleled experience in their respective areas, and their input to our MAN-01 program is tremendously valuable. We are excited to have them both on board and look forward utilizing their experience beyond MAN-01, as we continue to grow our pipeline.”
Denis Corin, CEO of Q BioMed Inc added, “We are very pleased to welcome Amy and Rick and the extensive knowledge and experience they bring to our advisory board and we look forward to their input in all areas of our expanding pipeline”.

Please visit our website www.qbiomed.com to sign up for regular updates and stay up-to-date with our progress.

About Q BioMed Inc.

Q BioMed Inc.”Q“ is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital the need to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Denis Corin

CEO

Q BioMed Inc.

1 888 357 2435

Source: Q BioMed Inc.

New Treatment in Development Looks to Treat Rare Condition that Robs Approximately 20,000 US Children per Year of their Ability to Speak

NEW YORK, April 25, 2017 —  Q BioMed Inc. (OTCQB: QBIO) and ASDERA LLC today announce a licensing agreement that provides Q BioMed with the worldwide exclusive rights to ASDERA’s ASD-002, which is being developed to treat a rare pediatric nonverbal disorder. Under the terms of the agreement, Q BioMed receives global rights to develop and commercialize the drug in the rare pediatric disease market.

Among the more than 60,000 US children who develop autism spectrum disorders (ASD) every year, 20,000 become nonverbal or lose the ability to speak. The numbers are similar in Europe and this nonverbal group will have to rely on assisted living for the rest of their life.

Denis Corin, CEO of Q BioMed said, “Given the severity of this disorder, and the immense emotional toll on these children and their families, our goal is to move the product forward quickly by using all the regulatory tools available to us to expedite the advancement of this drug candidate.”

The cost for treatment and assisted living in the US alone can equal or exceed ten million dollars per patient over a lifetime. The estimated cost to the US healthcare system and lost productivity is estimated at 200 billion dollars each. Currently there is no treatment for this disorder.  EEG, behavioral, and  genetic testing can identify a very targeted population of children in their second year of life that we believe would respond to this treatment.

Research published in 2014 by Wittkowski et al in the Nature journal Translational Psychiatry and independently confirmed in 2015 by Gugliemi et al indicated that certain ion channels were not active enough in this targeted population. ASD-002 is designed to ameliorate this age-specific condition by activating these ion channels. If the second year of life treatment window is missed, many of these children may lose the ability to speak while others may never start to speak at all.

“We are very excited about the potential of ASD-002 and hopefully this will allow thousands of children each year to develop speech and live independent and productive lives,” added Corin.

“ASDERA’s mission is to focus on developing targeted therapies for diseases where there is a high unmet need,” said Dr. Knut Wittkowski. “We are grateful to be working with Q BioMed, which immediately saw the potential of ASD-002 and are committed to ensuring that ASD-002 reaches its intended target patient population.”

About This Rare Pediatric Nonverbal Disorder

Early physiological and behavioral signs of becoming nonverbal appear around nine months of age and include: excessive crying, abnormal eye tracking, and epileptiform EEG. These children may never speak or might begin speaking a few words and then “regress” and lose their ability to speak, while developing on the autism spectrum. Pathological symptoms manifest at the age of 24 months, at which age post-mortem scans  reveal patchy regions of disorganization in cortical brain regions.

Research Papers:

• Wittkowski KM, Sonakya V, Bigio B, Tonn MK, Shic F, Ascano M, Nasca C, Gold-Von Simson G. A novel computational biostatistics approach implies impaired dephosphorylation of growth factor receptors as associated with severity of autism. Transl Psychiatry. 2014;4:e354. PMCID: 3905234. Available from: http://www.nature.com/articles/tp2013124.
• Guglielmi L, Servettini I, Caramia M, Catacuzzeno L, Franciolini F, D’Adamo MC, Pessia M. Update on the implication of potassium channels in autism: K(+) channelautism spectrum disorder. Front Cell Neurosci. 2015;9:34. PMCID: 4345917. Available from: https://doi.org/10.3389/fncel.2015.00034

Please visit www.qbiomed.com and sign up to stay up-to-date on our developments.

About ASDERA

ASDERA is a privately held biotech company, whose mission is to provide solutions for diseases with high unmet needs. The results leading to ASD-002 were derived using a proprietary discovery platform that uniquely analyzes genetic data to identify collections of functionally related genes and, thus, possible drugs to modulate these functions. This platform has also been successfully applied to analyze clinical trials to identify targeted patient populations more likely to respond to therapy.

http://www.asdera.com/autism.html

Q BioMed Inc.

Q BioMed Inc. is a BioMedical acceleration and development company focused on licensing and acquiring BioMedical assets across the healthcare spectrum. It is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their potential, enabling them to provide products to patients in need‏.

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Denis Corin

CEO

Q BioMed Inc.

1 888 357 2435

info@qbiomed.com

Source: Q BioMed Inc.

COMPANY EXPECTS REVENUE FROM BONE PAIN DRUG AHEAD OF SCHEDULE

NEW YORK, June 7, 2017 — Q BioMed Inc. (OTCQB: QBIO), is very pleased to announce that the company has initiated production of Strontium-89 Chloride, a radiopharmaceutical indicated for the analgesic treatment of metastatic breast and prostate cancer bone pain.

Denis Corin, CEO of the Company said, “This is a major milestone in our short history. We are very excited to bring this product to market less than one year after finalizing the licensing agreement. There is an acute demand for an affordable and effective alternative to opiate based drugs in this patient population. We know this proven drug is effective and well tolerated with limited side-effects. We look forward to making it available as widely as possible and as quickly as possible. We believe there is significant opportunity to build this franchise and expand the revenue opportunity associated with it.”

Approximately 70% of patients with advanced breast and prostate cancer metastases will develop bone metastases, an extremely painful condition. Bone metastases occur in most tumor types but are most prevalent in cancers of the breast, prostate, and lung. These bone lesions can cause serious skeletal complications, including spinal cord or nerve root compression, hypercalcemia of malignancy, pathologic fractures, and severe bone pain which can significantly compromise quality of life and may negatively affect survival. Palliation of pain, prevention of skeletal complications, and maintenance of quality of life are the primary objectives in managing patients with metastatic bone disease.

AB-Rated Strontium Chloride Sr89 Injection USP (Sr89) can be used in combination with or to reduce the need for opiate based drugs, as well as in combination with cancer therapeutic drugs. After administration, pain relief can occur in as little as one to two weeks and can last several months, when another dose can be administered with minimal side effects. Clinical studies have demonstrated that for many, the combination of alternating weekly chemohormonal therapies with Sr89 demonstrated a prolonged and progression-free survival.

We expect to provide more information regarding initial commercialization in the coming weeks.

Please visit our website http://www.qbiomed.com to sign up and stay up-to-date with our progress.

About Strontium-89 Chloride

Following intravenous injection, soluble strontium compounds behave like their calcium analogs, clearing rapidly from the blood and selectively localizing in bone mineral. Uptake of strontium by bone occurs preferentially in sites of active osteogenesis; thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone. Strontium-89 Chloride is retained in metastatic bone lesions much longer than in normal bone, where turnover is about 14 days. In patients with extensive skeletal metastases, well over half of the injected dose is retained in the bones. Excretion pathways are two-thirds urinary and one-third fecal in patients with bone metastases. Urinary excretion is higher in people without bone lesions. Urinary excretion is greatest in the first two days following injection. Strontium-89 is a pure beta emitter and Strontium-89 Chloride selectively irradiates sites of primary and metastatic bone involvement with minimal irradiation of soft tissues distant from the bone lesions. (The maximum range in tissue is 8 mm; maximum energy is 1.463 MeV.) Clinical trials have examined relief of pain in cancer patients who have received therapy for bone metastases (external radiation to indexed sites) but in whom persistent pain recurred.

INDICATIONS AND USAGE: Strontium-89 Chloride Injection is indicated for the relief of bone pain in patients with painful skeletal metastases. The presence of bone metastases should be confirmed prior to therapy.

CONTRAINDICATIONS:  None known.

WARNINGS: Use of Strontium-89 Chloride (Sr89) in patients with evidence of seriously compromised bone marrow from previous therapy or disease infiltration is not recommended unless the potential benefit of the treatment outweighs its risks. Bone marrow toxicity is to be expected following the administration of Strontium-89 Chloride, particularly white blood cells and platelets. The extent of toxicity is variable. It is recommended that the patient’s peripheral blood cell counts be monitored at least once every other week. Typically, platelets will be depressed by about 30% compared to preadministration levels. The nadir of platelet depression in most patients is found between 12 and 16 weeks following administration of Sr89. White blood cells are usually depressed to a varying extent compared to pre-administration levels. Thereafter, recovery occurs slowly, typically reaching pre-administration levels six months after treatment unless the patient’s disease or additional therapy intervenes. In considering repeat administration of Sr89, the patient’s hematologic response to the initial dose, current platelet level and other evidence of marrow depletion should be carefully evaluated. Verification of dose and patient identification is necessary prior to administration because Strontium-89 Chloride delivers a relatively high dose of radioactivity. Strontium-89 Chloride may cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.

About Q BioMed Inc.

Q BioMed Inc.”Q“ is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital the need to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Dennis Corin

CEO

Q BioMed Inc.

1 888 357 2435

Source: Q BioMed Inc.

COMPANY EXECUTIVES AND TECHNOLOGY PARTNERS TO ATTEND INDUSTRY GATHERING JUNE 10-14 2017

NEW YORK, June 9, 2017 — Q BioMed Inc. (OTCQB: QBIO), and executives from its advanced technology partner Bio-Nucleonics Inc. will attend the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting that is being held in Denver, Colorado June 10 – 14, 2017. The SNMMI annual meeting brings together leading nuclear medicine physicians, scientists and technologists from leading medical and academic centers.

The meeting provides an ideal location to meet with collaborators, vendors and partners working on the recently announced commercialization of Strontium-89 Chloride (Sr89). Sr89 Injection USP is a non-opioid analgesic indicated for the relief of bone pain in patients with painful skeletal cancer metastases.

Approximately 70% of patients with advanced breast and prostate cancer metastases will develop bone metastases, an extremely painful condition. Bone metastases occur in most tumor types but are most prevalent in cancers of the breast, prostate, and lung. These bone lesions can cause serious skeletal complications, including spinal cord or nerve root compression, hypercalcemia of malignancy, pathologic fractures, and severe bone pain which can significantly compromise quality of life and may negatively affect survival. Palliation of pain, prevention of skeletal complications, and maintenance of quality of life are the primary objectives in managing patients with metastatic bone disease.

AB-Rated Strontium Chloride Sr89 Injection USP (Sr89) can be used in combination with or to reduce the need for opiate based drugs, as well as in combination with cancer therapeutic drugs. After administration, pain relief can occur in as little as one to two weeks and can last several months, when another dose can be administered with minimal side effects. Clinical studies have demonstrated that for many, the combination of alternating weekly chemohormonal therapies with Sr89 demonstrated a prolonged and progression-free survival.

Please visit our website http://www.qbiomed.com to sign up and stay up-to-date with our progress.

About Strontium-89 Chloride

Following intravenous injection, soluble strontium compounds behave like their calcium analogs, clearing rapidly from the blood and selectively localizing in bone mineral. Uptake of strontium by bone occurs preferentially in sites of active osteogenesis; thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone. Strontium-89 Chloride is retained in metastatic bone lesions much longer than in normal bone, where turnover is about 14 days. In patients with extensive skeletal metastases, well over half of the injected dose is retained in the bones. Excretion pathways are two-thirds urinary and one-third fecal in patients with bone metastases. Urinary excretion is higher in people without bone lesions. Urinary excretion is greatest in the first two days following injection. Strontium-89 is a pure beta emitter and Strontium-89 Chloride selectively irradiates sites of primary and metastatic bone involvement with minimal irradiation of soft tissues distant from the bone lesions. (The maximum range in tissue is 8 mm; maximum energy is 1.463 MeV.) Clinical trials have examined relief of pain in cancer patients who have received therapy for bone metastases (external radiation to indexed sites) but in whom persistent pain recurred.

INDICATIONS AND USAGE: Strontium-89 Chloride Injection is indicated for the relief of bone pain in patients with painful skeletal metastases. The presence of bone metastases should be confirmed prior to therapy.

CONTRAINDICATIONS:  None known.

WARNINGS: Use of Strontium-89 Chloride (Sr89) in patients with evidence of seriously compromised bone marrow from previous therapy or disease infiltration is not recommended unless the potential benefit of the treatment outweighs its risks. Bone marrow toxicity is to be expected following the administration of Strontium-89 Chloride, particularly white blood cells and platelets. The extent of toxicity is variable. It is recommended that the patient’s peripheral blood cell counts be monitored at least once every other week. Typically, platelets will be depressed by about 30% compared to preadministration levels. The nadir of platelet depression in most patients is found between 12 and 16 weeks following administration of Sr89. White blood cells are usually depressed to a varying extent compared to pre-administration levels. Thereafter, recovery occurs slowly, typically reaching pre-administration levels six months after treatment unless the patient’s disease or additional therapy intervenes. In considering repeat administration of Sr89, the patient’s hematologic response to the initial dose, current platelet level and other evidence of marrow depletion should be carefully evaluated. Verification of dose and patient identification is necessary prior to administration because Strontium-89 Chloride delivers a relatively high dose of radioactivity. Strontium-89 Chloride may cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.

About Q BioMed Inc.

Q BioMed Inc.”Q“ is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital the need to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Dennis Corin

CEO

Q BioMed Inc.

1 888 357 2435

Source: Q BioMed Inc.

Company To Present at 9:30am ET June 15th 2017 at the Grand Hyatt

NEW YORK, June 14 2017 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today that it will be a featured presenter at the 6th Annual Marcum MicroCap Conference on Thursday, June 15, 2017 in New York City at the Grand Hyatt Hotel.

The Company’s presentation by Denis Corin, Q BioMed Inc. CEO, is scheduled to begin at 9:30a.m ET on Thursday June 15th in the Julliard Room. The presentation will cover the company’s business strategy, pipeline, recent developments and look forward at milestones for the balance of 2017 and beyond.

The presentation will be webcast, please visit this address to attend the webcast http://wsw.com/webcast/marcum5/qbio

Since its launch in 2012, this event has become a nationally recognized forum for publicly traded companies with less than $500 million in market capitalization to network with fund managers and high net worth investors who focus on small cap equities. More than 2,000 participants from all segments of the microcap market participate each year, including senior management, finance and legal executives, venture and lower middle-market private equity investors, institutional investors, directors, investment bankers, buy- and sell-side analysts, and service providers to the microcap marketplace.

Please sign up for company updates at www.qbiomed.com to stay informed and up-to-date with company developments.

Follow us on Twitter @QBioMed

About Q BioMed Inc.

Q BioMed Inc. ”Q“ is a biomedical acceleration and development company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q is dedicated to providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

About Marcum LLP

Marcum LLP is one of the largest independent public accounting and advisory services firms in the nation, with offices in major business markets throughout the U.S., Grand Cayman and China. Headquartered in New York City, Marcum provides a full spectrum of traditional tax, accounting and assurance services; advisory, valuation and litigation support; and an extensive range of specialty and niche industry practices. The Firm serves both privately held and publicly traded companies, as well as high net worth individuals, private equity and hedge funds, with a focus on middle-market companies and closely held family businesses. In 2015, Marcum’s SEC Services Practice group led all non-“Big Four” accounting firms in the performance of audits in connection with Initial Public Offerings (“IPOs”).  Marcum is a member of the Marcum Group, an organization providing a comprehensive array of professional services. For more information, visit www.marcumllp.com.

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are:u risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Denis Corin

CEO

Q BioMed Inc.

1 888 357 2435

NEW YORK, June 15, 2017 /PRNewswire/ —

Q BioMed Inc. (QBIO), is very pleased to announce their entry into a final license agreement with The Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB). Under the agreement QBioMed has the global exclusive rights to develop and market a novel chemotherapeutic drug to treat liver cancer.

The compound was isolated and characterized from the leaves of Solanum nigrum Linn, or black nightshade, a plant widely used in traditional medicine.

In animal models, the compound, called uttrocide B, was shown to be 10 times more cytotoxic to HepG2 liver cancer cells than the only drug currently on the market for the condition.

“Our ultimate goal is to use uttrocide B as a chemotherapeutic against liver cancer, which has very few therapeutic options,” said Q BioMed, Inc., CEO Denis Corin.

RGCB researchers identified the therapeutic effect of the compound and then entered into collaboration with OMRF to further develop and commercialize it. In animal models, uttrocide B was shown to be more potent than the currently available drug for the disease and caused no noticeable side effects.

“We are excited at the prospect of developing a drug that could address a significant unmet medical need and benefit patients”, said Dr. M.R.Pillai, Director of RGCB.

Liver cancer is the second most common cause of cancer deaths worldwide, according to the Centers for Disease Control and Prevention, and claims approximately 750,000 lives each year. The American Cancer Society estimates that 39,000 people in the U.S. will be diagnosed with primary liver cancer in 2017 and that 27,000 will die from the disease this year.

“This is truly an unmet need in liver cancer,” said OMRF Vice President of Technology Ventures, Manu Nair. “To find a plant-based treatment for a condition like liver cancer can open the door to a wide variety of other natural products for treating human disease.”

Please visit http://www.qbiomed.com for more information and sign up to receive regular updates. Follow us on Twitter @QBioMed.

About OMRF

OMRF (omrf.org) is an independent, nonprofit biomedical research institute dedicated to understanding and developing more effective treatments for human diseases. Its scientists focus on such critical research areas as cancer, diseases of aging, lupus and cardiovascular disease.

About RGCB

RGCB is an autonomous national institution fully-owned by the Government of India. It does pioneering research in cellular and molecular mechanisms of human animal and plant disease by amalgamating theory, modeling, simulation and experimental science.

About Q BioMed, Inc.

Q BioMed, Inc., (Q) is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support and expansion capital they need to ensure they meet their developmental potential, enabling them to provide products to patients in need.

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:
Dennis Corin, CEO
Q BioMed Inc.
+1-888-357-2435

NEW YORK, June 26 2017 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today that Christopher Manuele will join the Strontium 89 Chloride commercialization team.
Mr. Manuele is a results-oriented, innovative executive with thirty-five years of comprehensive US and International expertise in nuclear medicine and medical isotope production. A long-time veteran of Amersham Health and GE Healthcare, he has launched core products; expanded products internationally; led the design, construction and FDA-approval of two brand new U.S. manufacturing facilities; and held responsibility for several full-GMP radiopharmaceutical manufacturing sites across the US and Europe. Before his retirement in 2008, Mr. Manuele served as General Manager – Global Nuclear Medicine Supply Chain for GE Healthcare, and General Manager – Oncura, GE’s global I-125 brachytherapy seeds business. He has an impeccable track record of operational excellence, continuous profitability improvement, and implementation of industry-leading quality systems.
Mr. Manuele joins our VP of Product Development and equally experienced David Laskow-Pooley in directing the roll out and development of the Strontium 89 product. Mr. Laskow-Pooley has 40 years of experience in all aspects of the discovery, development and commercialization of pharmaceutical products, diagnostics and devices. He is an industry veteran and has a distinguished career working for numerous pharmaceutical and life sciences companies. David has held director, executive officer and general management posts in both small and major multinational companies including GSK, Abbott, Amersham plc, Life technologies, OSI, Bilcare and Surface Therapeutics. At Amersham Plc (now part of GE Healthcare) he was a member of the senior executive team and during his tenure there he led strategy development, commercial operations and manufacturing with responsibility globally for all of the Amersham nuclear facilities.
Together with the team at our technology partner BioNucleonics, we have a very capable and experienced team to support the roll out and growth of this product.
Please sign up for company updates at www.qbiomed.com to stay informed and up-to-date with company developments.
Follow us on Twitter @QBioMed

About Q BioMed Inc.
Q BioMed Inc. ”Q“ is a biomedical acceleration and development company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q is dedicated to providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

About Strontium-89 Chloride
Following intravenous injection, soluble strontium compounds behave like their calcium analogs, clearing rapidly from the blood and selectively localizing in bone mineral. Uptake of strontium by bone occurs preferentially in sites of active osteogenesis; thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone. Strontium-89 Chloride is retained in metastatic bone lesions much longer than in normal bone, where turnover is about 14 days. In patients with extensive skeletal metastases, well over half of the injected dose is retained in the bones. Excretion pathways are two-thirds urinary and one-third fecal in patients with bone metastases. Urinary excretion is higher in people without bone lesions. Urinary excretion is greatest in the first two days following injection. Strontium-89 is a pure beta emitter and Strontium-89 Chloride selectively irradiates sites of primary and metastatic bone involvement with minimal irradiation of soft tissues distant from the bone lesions.

Forward-Looking Statements:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are:u risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Denis Corin
CEO
Q BioMed Inc.
1 888 357 2435

Q BIOMED INC. CLOSES $3,050,390 EQUITY FINANCING

Funding Provides Capital to Meet Near Term Milestones and Catalysts

Q BioMed Inc. (QBIO) is pleased to announce the closing of a $3,050,390 equity financing. The financing with a small group of accredited investors provides the necessary capital to meet near term milestones and catalysts in its most advanced product portfolio assets, including the commercialization of Strontium Chloride 89, multiple IND enabling studies, CMC manufacturing and at least one IND filing.
Pursuant to the securities purchase agreement, accredited investors received 953,247 units with each unit consisting of one share of our common stock priced at $3.20 and a five-year warrant to purchase one additional share of our common stock at $4.50.
Denis Corin, CEO QBioMed Inc., said, “This capital provides the runway we need to meet some significant milestones over the next few months. We are eagerly anticipating Sr89 commercial production, which is in final QC and validation. Also the pre-IND work on QBM001 for the treatment of young children with a rare autistic spectrum disorder causing them to lose the ability to speak, is expected to be complete and a submission to the regulators for IND is expected before year end.”
Brookline Capital markets, a division of CIM Securities, LLC acted as the exclusive placement agent for the offering.
For more information, please refer to our Form 8K filed today.
Please visit our website http://www.qbiomed.com and follow us on social media @QBioMed to stay updated on our progress.
About Q BioMed, Inc.
Q BioMed, Inc., (Q) is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support and expansion capital they need to ensure they meet their developmental potential, enabling them to provide products to patients in need.
Forward-Looking Statements:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Contact:
Dennis Corin
CEO, Q BioMed Inc.
+1-888-357-2435

http://consumer.healthday.com/eye-care-information-13/eye-and-vision-problem-news-295/researchers-probe-molecular-cause-for-glaucoma-691598.html